OCEANIC-AF trial reveals inferiority of asundexian to apixaban for stroke prevention

Asundexian 50 mg daily was inferior to apixaban for stroke and systemic embolism prevention in high-risk patients with atrial fibrillation (AF), according to late-breaking research presented in a Hot Line session today at ESC Congress 2024.

Surprising link between a diverse oral microbiome and better cognitive function in aging

Study found that higher oral microbiome diversity is linked to better cognitive function and fewer memory issues in older US adults, highlighting the “oral-brain axis.”

June 10, 2024

New therapy shows promise in treating basal cell carcinoma

Basal cell carcinomas, the most common form of skin cancer, occur in chronically sun-exposed areas such as the face.

January 27, 2025

Doctors Without Borders challenges pharma by releasing costs for a key clinical trial

In a challenge to the pharmaceutical industry, Doctors Without Borders has revealed the detailed costs of a study it ran for a tuberculosis treatment regimen

April 29, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.